Reading The Tea Leaves For PD-1 Family In New Hematology Data
This article was originally published in Pharmaceutical Approvals Monthly
Nivolumab investigator, ASH presidential symposium speaker and translational biologist Margaret Shipp explains in an interview why PD-1 blockade might be better in Hodgkin lymphoma than PD-L1 inhibition, and contemplates the future in other blood diseases.
You may also be interested in...
Immune Checkpoint Blockade: The New Big Idea In Cancer
Biologics that target immune checkpoints co-opted by cancer resistance have been significantly de-risked by the success of Bristol’s immunotherapy Yervoy and the progress of its Phase III candidate nivolumab. With six companies now testing candidates in the clinic, the class promises to have a big impact on oncology over the next several years, with the possibility of a next-generation approval by 2015.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.